GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.
J Clin Transl Endocrinol
; 35: 100333, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38449772
ABSTRACT
Objective:
Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.Methods:
Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.Results:
Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.Conclusion:
Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
J Clin Transl Endocrinol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos